Sarepta Therapeutics, Inc. (SRPT)’s Bullish Double Top Points to Lower Stock Risks

April 24, 2018 - By Vivian Park

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Logo

Investors sentiment decreased to 1.22 in 2017 Q4. Its down 1.66, from 2.88 in 2017Q3. It is negative, as 27 investors sold Sarepta Therapeutics, Inc. shares while 67 reduced holdings. 45 funds opened positions while 70 raised stakes. 52.88 million shares or 2.28% more from 51.70 million shares in 2017Q3 were reported.
Rock Springs Management Limited Partnership has invested 0.65% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Price T Rowe Associates Inc Md owns 1.87M shares. Qvt Lp has 17,231 shares for 0.05% of their portfolio. Strs Ohio has 0% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 6,200 shares. Nokota Lp stated it has 80,020 shares or 0.09% of all its holdings. Meeder Asset Mngmt reported 0% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Washington-based Fisher Asset Mngmt Limited Liability Co has invested 0% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Gilder Gagnon Howe Ltd Liability holds 0.65% or 872,824 shares in its portfolio. Moreover, Crow Point Limited Liability Corp has 0.01% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Alps accumulated 71,619 shares. Natixis invested in 0.01% or 13,560 shares. Amer Intl Group Inc Inc owns 41,166 shares. Aperio Gru Ltd Liability Co holds 3,936 shares. Hightower Advsrs Limited Liability Company reported 0.03% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Raymond James & invested in 24,353 shares.

The chart of Sarepta Therapeutics, Inc. (SRPT) shows a double top with $82.96 target or 9.00 % above today’s $76.11 share price. The 5 months chart pattern indicates low risk for the $4.95 billion company. It was reported on Apr, 24 by If the $82.96 price target is reached, the company will be worth $445.05M more. Double tops are rare but powerful chart patterns.

The stock decreased 2.82% or $2.2 during the last trading session, reaching $76.11. About 424,098 shares traded. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has risen 149.90% since April 24, 2017 and is uptrending. It has outperformed by 138.35% the S&P500.

Analysts await Sarepta Therapeutics, Inc. (NASDAQ:SRPT) to report earnings on April, 26. They expect $-0.32 EPS, up 56.16 % or $0.41 from last year’s $-0.73 per share. After $-0.37 actual EPS reported by Sarepta Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -13.51 % EPS growth.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Ratings Coverage

Among 14 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 12 have Buy rating, 0 Sell and 2 Hold. Therefore 86% are positive. Sarepta Therapeutics has $100 highest and $49 lowest target. $80.08’s average target is 5.22% above currents $76.11 stock price. Sarepta Therapeutics had 24 analyst reports since October 26, 2017 according to SRatingsIntel. The company was maintained on Friday, March 2 by Piper Jaffray. The rating was initiated by RBC Capital Markets with “Buy” on Monday, January 22. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has “Buy” rating given on Wednesday, February 21 by J.P. Morgan. JP Morgan maintained the stock with “Overweight” rating in Wednesday, March 14 report. Morgan Stanley downgraded the stock to “Equal-Weight” rating in Wednesday, March 21 report. The firm earned “Buy” rating on Monday, March 12 by Piper Jaffray. The rating was maintained by Leerink Swann on Friday, January 19 with “Buy”. The company was maintained on Thursday, October 26 by Barclays Capital. The company was maintained on Friday, February 9 by Piper Jaffray. Needham maintained Sarepta Therapeutics, Inc. (NASDAQ:SRPT) on Thursday, October 26 with “Buy” rating.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.